Browsing Tag
Bill Meury
2 posts
Incyte (Nasdaq: INCY) Q2 2026 revenue jumps 38% as CMS Opzelura settlement lifts headline growth
Incyte Q2 revenue jumped 38% on a $246m CMS Opzelura benefit, but the underlying growth line and $1.27bn Vega charge redraw the 2026 investment case.
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.